Clinical Trial Update: Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast [Phase 1]

View source ↗

Summary

Completed Phase 1 biodistribution study evaluating a 186Re-labelled humanised monoclonal antibody BIWA-4 in patients with breast cancer (adenocarcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BIWA 4

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Adenocarcinoma | Phase 1 | Status: COMPLETED